Under construction – not a live service
Sign in
Taking people in CanadaPhase 2

Testing a focal radiation boost with stereotactic radiotherapy for prostate cancer

Tests a focal brachytherapy boost added to radiotherapy in men with prostate cancer.

Key facts

Who runs it
Centre hospitalier de l'Université de Montréal (CHUM)
Where
Montreal and Québec, CanadaSee the 2 sites
Trial code
Registry title
Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy
Status
Recruiting
Phase
Phase 2
People taking part
150 people, planned
Started
1 Jul 2019
Planned end
30 Jun 2025
Type of study
Interventional
Treatments tested
  • focal brachytherapy boost to SBRT
Record updated
13 March 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with biopsy-proven prostate cancer who are planned for an HDR brachytherapy boost together with external beam radiotherapy, with the aim of removing all of the disease.

Sex
Men only.
Disease stage
Disease seen on imaging must cover less than 50% of the prostate gland and agree with the biopsy findings.

Main reasons for not taking part

  • The record lists no exclusion criteria.
  • Performance status must be ECOG 0-1 and Charlson Comorbidity Index 4 or lower.

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Histological diagnosis of prostate cancer planned for curative-intent HDR brachytherapy boost to external beam radiotherapy to the prostate gland
  • ECOG 0-1
  • Charlson Comorbidity Index ≤ 4
  • Imaging visible disease encompassing < 50% of the prostate gland and consistent with biopsy findings; Exclusion - none

Where in Canada

  • Centre Hospitalier de l'Université de MontréalMontreal, CanadaContact: Mom PhatTaking people
  • CHUQQuébec, CanadaContact: Josee AllardTaking people

About the trial

What the trial wants to find out

To determine if fBT+sRT is superior to standard care in terms of urinary toxicity by having fewer patients experience a minimal important decline (MID) in urinary irritation/obstructive QoL

Treatments tested

  • focal brachytherapy boost to SBRT

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy
Plain-language title
Testing a focal radiation boost with stereotactic radiotherapy for prostate cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
13 March 2025